Fractyl Health (NASDAQ:GUTS) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Fractyl Health (NASDAQ:GUTS) released its quarterly earnings results on Monday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.08), Zacks reports.

Fractyl Health Stock Performance

Shares of GUTS opened at $1.56 on Tuesday. The company has a current ratio of 5.58, a quick ratio of 5.57 and a debt-to-equity ratio of 0.60. The stock has a market cap of $75.03 million and a P/E ratio of -0.13. The company has a 50-day moving average of $1.77 and a two-hundred day moving average of $2.28. Fractyl Health has a 12-month low of $1.37 and a 12-month high of $10.50.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reduced their price objective on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd.

Insider Activity

In other Fractyl Health news, CEO Harith Rajagopalan sold 90,972 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total transaction of $165,569.04. Following the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $894,218.78. This represents a 15.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jay David Caplan sold 22,346 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.81, for a total transaction of $40,446.26. Following the completion of the transaction, the insider now owns 153,544 shares of the company’s stock, valued at $277,914.64. This represents a 12.70 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.